Features

Special Topic

New insight from MASTER DAPT

MASTER DAPT Complex PCI sub-analysis presented at EuroPCR 2022. You can download it here.

MASTER DAPT result

Click here to download a summary of trial primary endpoints.

Reliable Biodegradable polymer-DES

Overview

Point 1

The most studied BP-DES, over 50,000 patients world wide

Point 2

The biggest real world BP-DES registry shows favorable clinical performance

The most studied BP-DES, over 50,000 patients world wide^1,2

Ultimaster™ has been studied worldwide by enrolling over 50,000 patients in Terumo sponsored trial and investigator sponsored research. The clinical programs have consistently shown favorable efficacy and safety of Ultimaster™ even in complex lesions.

	Number of patients	Design	Primary outcomes	Sub Study
MASTER DAPT	4300	Investigator-initiated, randomized, short vs standard DAPT	NACE, MACCE, MCB at 11 months (12 months post-index PCI)	Enrolling, protocol published
e-Ultimaster	37,198	Single arm, all-comers, real-world use	TLF at 1 year	Completed and accepted for publication
CENTURY II	1123	Randomised 1:1 vs Xience	Freedom from TLF at 9 months	Published and completed
DISCOVERY 1TO3	60	Single arm, patients with multivessel disease	OFDI strut coverage at 3 months	Published and completed
MODEL U-SES	1,695	Prospective multicenter, single-arm registry, Investigators initiated study	Composite endpoint of all-cause death, MI, stroke, ARC definite / probable stent thrombosis, and BARC 3 or 5 during 12months after stenting	Published and completed
SCAAR	3,253	Multicenter registry in Sweden	ST, Restenosis rate	Enrolling
SCC registry	1,727	Single arm, all-comers, single center study	TLR, TLF, MACE	Published and completed
ULISS	1,660	Single arm, all-comers, single center study	TLR, TLF, Composite endpoint of cardiac death, TV-MI	Published and completed
MASTER	500	Randomized 3:1 vs BMS in patients with STEMI	Safety at 1 month, efficacy at 6 months, safety and efficacy at 12 months	Published and completed
COLOR	388	Investigator-initiated, randomized complexed large-bore radial PCI trial	BARC bleeding or vascular complication related to access site	Enrolling
CENTURY	105	Single arm, first-in-man study	Late loss at 6 months	Published and completed
CENTURY JSV	70	Single arm, patients requiring 2.25 mm diameter stents	Freedom from MACE at 9 months	Published and completed
TCD-10023PK	22	Single arm, pharmaco kinetics	Sirolimus concentration in peripheral blood samples 28 days after Ultimaster implantation	Published and completed

Learn more

The biggest real-world BP-DES registry shows favorable clinical performance³

The e-Ultimaster is a single arm, real world registry enrolled over 37,198 patients. Sub-study shows Ultimaster™’s favorable performance in the patient group including patients with complex lesions such as bifurcation lesion, LMT, CTO and MVD.

featured_ultimaster_features_37198patients_1844x819.png

Final result presented at PCR e-course2020

featured_ultimaster_features_study_design_1844x1395.png

Clinical outcomes at 1 year

featured_ultimaster_features_clinical_outcome_1844x1200.png

Learn more about e-Ultimaster

The Longest history BP-DES company⁴

Terumo launched world’s first biodegradable polymer DES in 2008. Ultimaster™ is terumo’s second BP-DES with a thin-strut flexible design contributing to long term patency developed by new biodegradable polymer technology.

featured_ultimaster_features_longest_bp_history_1844x912.png

Reference

Overview

Point 1

Reliable delivery in TRI

Point 2

Product feature

Point 3

Innovative tip

Point 4

Flexible stent design

Point 5

Advance shaft technology with traditional Terumo technology

Reliable delivery in TRI

Good transmission force even when the guiding catheter does not provide sufficient support¹

Ultimaster™ is designed to facilitate delivery for TRI. In TRI, guiding catheter sometime fails to provide sufficient back-up support, leading to guiding catheter disengagement in complex lesion treatment. Ultimaster™ supports not only delivery in challenging cases but also your thought for your patients.

Product feature

Terumo, TRI pioneer has made a contribution to develop of many products designed for TRI. Ultimaster™ is a also device dedicated for TRI which has an innovative tip, flexible stent design and advanced shaft technology with traditional Terumo hydrophilic coating.

Innovative tip

Terumo developed an innovative tip dedicated for drug eluting stent delivery. The conventional tip was designed by referring to PTCA balloon catheter. Terumo developed a new tip dedicated for DES from scratch. The newly developed rounded and durable tip minimize the clearance gap between the tip and guide wire.

Flexible stent design

Stent design is simple bioinspired designed with the practical sense of beauty. This stent design allowing maximization of the whole stent from distal edge to proximal edge. The maximized flexibility leads to good trackability especially in stent delivery in complex lesion treatment.

Advance shaft technology with traditional Terumo technology

Ultimaster™ was developed by applying both the advanced technology used for the Terumo PTCA balloon shaft and the traditional hydrophilic coating technology used for the Terumo guidewire. These technologies enhance pushability and trackability under challenging conditions such as TRI where back-up support from a guiding catheter is poor.

featured_ultimaster_features_advanced_shaft_technology_ryurei_880x544.png

featured_ultimaster_features_advanced_shaft_technology_guide_wire_880x544.png

Ryurei™ PTCA Balloon movie

Learn more about our product

Reference

Bifurcation Excellence

0% Cardiac Death

5 year follow up in Bifurcation sub study¹

featured_ultimaster_features_tlf_2.5%_880x544.png

2.5% TLF

5 year follow up in True bifurcation

Overview

Point 1

Wider over-expansion range

Point 2

Smooth side branch access by the biggest open cell size design

Point 3

Abluminal gradient coating technology ensure polymer integrity

Wider over-expansion range

Φ3.0~4.0mm DES is generally used for LMT stenting². Ultimaster™ has longer total crown length allowing wider over-expansion range.

Over expansion limit

Total crown length compared among major drug eluting stent design

Stent design forΦ4.0mm	Ultimaster™	Synergy	Xience Sierra	Resolute Onyx
Stent Design
Measured total crown length	21.5mm	19.8mm	20.1mm	15.2mm

Smooth side branch access by the biggest open cell size design

featured_ultimaster_features_smooth_side_branch_access_880x544.png

Side branch access is key parameter for stent selection in treatment of bifurcation lesion.⁵ Ultimaster™ has the uniform open cell design with the biggest cell size leading to smooth side branch access.

Total crown length compared among major drug eluting stent design

Stent design forΦ4.0mm	Ultimaster™	Synergy	Xience Sierra	Resolute Onyx
Stent Design
Measured total crown length	21.5mm	19.8mm	20.1mm	15.2mm
Maximum Cell Diameter	6.8mm	5.7mm	4.8mm	6.5mm
Maximum Cell Area	36.3mm²	25.7mm²	18.1mm²	33.2mm²

Abluminal gradient coating technology ensuring polymer integrity

Our products are manufactured by paying attention to the details. There is no drug coating on the stent platform at which high stress is concentrated when stent is over-expanded. Ultimaster™ keeps polymer integrity even when the stent is expanded to the maximum diameter.

Polymer integrity at the maximum diameter⁷